Company intelligence / Profile preview

Qinghai Everest Cordyceps Sinensis Pharmaceutical

Qinghai, China

Ownership: Private
Development stage: Other

Overview

The company manufactures fermented Cordyceps sinensis products as substitutes for natural Cordyceps sinensis. Fermented products contain similar chemical components to natural cordyceps, including amino acids and mannitol, and meet standards of the Pharmacopoeia of the People's Republic of China.[8] Research demonstrates these fermented products have antioxidant properties with selective effects on heart and liver tissues.

Therapeutic areas: ImmunologyOtherCardiovascularPulmonologyRheumatologyMetabolic DisordersOncologyMen's Health
Modalities: Herbal extractFermented fungal productTraditional Chinese medicine preparation
Industry: Biotech

Partnerships

Zhejiang Jolly Pharmaceutical (acquired 30% stake as of 2017)

Beyond the preview

Go deeper on Qinghai Everest Cordyceps Sinensis Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qinghai Everest Cordyceps Sinensis Pharmaceutical.

Explore the full profile